Eloralintide
Clinical evidenceEli Lilly's copy of the fullness hormone amylin, showing a remarkable 20% weight loss from a mechanism that skips GLP-1 entirely.
What it is
Eloralintide is a lab-engineered version of amylin, the hormone your pancreas releases at a meal to tell your brain you are done eating. It is a 37-amino-acid peptide built to last much longer than the natural version. One strong 48-week trial showed about 20% average weight loss, the largest number published for any amylin analog.
How it works
It signals fullness through the area postrema in the brainstem, a pathway completely separate from GLP-1 and GIP. By strengthening the body's sense of being full, it drives weight loss without touching the incretin axis that most other weight drugs use.
What people report
- ✦About 20% mean weight loss at 48 weeks in a randomized placebo-controlled phase 2 trial
- ✦Driven by a single non-incretin satiety mechanism
- ✦Most of the weight lost was fat, per the sponsor's analysis
- ✦Being studied alongside incretin drugs on the theory the two stack
Typical use
No approved protocol; phase 3 trials are still enrolling, with earliest results expected around 2028.
Dosing reference
Trial doses reached 9 mg weekly by injection, but there is no approved label. Verify against published trial data before any research use.
Reference only — not a recommendation. Verify via primary sources.
Watch for
The headline number rests on a single trial, and all studies are sponsor-run. The nausea story that justifies the design held for 12 weeks and then broke: nausea hit 64% in one fixed-dose arm at 48 weeks.
Educational content — not medical advice.